BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Benzinga Newsdesk www.benzinga.com Neutral 48.1%

Neg 0% Neu 48.1% Pos 0%

BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $27 to $24.